Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dalpiciclib by Jiangsu Hengrui Medicine for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Human Epidermal Growth Factor Receptor...
Dalpiciclib by Jiangsu Hengrui Medicine for Well Differentiated Liposarcoma: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Well Differentiated Liposarcoma. According to...
Dalpiciclib by Jiangsu Hengrui Medicine for Breast Cancer: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Breast Cancer. According to GlobalData,...
Dalpiciclib by Jiangsu Hengrui Medicine for Endometrial Cancer: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Endometrial Cancer. According to GlobalData,...
Dalpiciclib by Jiangsu Hengrui Medicine for Dedifferentiated Liposarcoma: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData,...
Dalpiciclib by Jiangsu Hengrui Medicine for Metastatic Ovarian Cancer: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Ovarian Cancer. According to...
Dalpiciclib by Jiangsu Hengrui Medicine for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Hormone-Sensitive Prostate Cancer. According to...